Free Newsletter
Transgene shares up on positive cancer vax data
Shares of France's Transgene jumped about 10 percent on Monday after new data from a Phase IIb trial of TG4010 demonstrated a survival benefit for non-small cell lung cancer patients. The French biotech noted that 39 percent of the patients receiving the vaccine combined with chemotherapy were still alive after 17 months of median follow-up, compared to 23 percent of the patients receiving chemotherapy alone.
A subpopulation of patients with a normal blood level of Natural Killer cells did even better. Researchers say they had an increased median survival rate of 6.7 months.
"We are delighted by the additional clinical data announced today, which once again validates our technological platform of immunotherapeutic products and our past investment in TG4010," said CEO Philippe Archinard. "Overall, these results are extremely promising."
- read the press release
Related Articles:
Transgene to partner after cancer vax passes trial
Deaths force halt to Cell Genesys cancer vaccine trial
Avant shares soar on positive cancer vaccine data
Antigenics gets world's first cancer vaccine approval
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
